Chronic administration of the somatostatin analogue SMS 201-995 does not lead to endogenous antibody formation.
Plasma samples of seven patients with gut and pancreatic endocrine tumours who have been on long-term treatment with a long-acting somatostatin analogue (SMS 201-995) were investigated for endogenous antibodies to the peptide by incubation with radiolabelled SMS 201-995. The duration of treatment with the somatostatin analogue was between 9 and 26 months and the dose from 100 to 300 micrograms day-1. In none of the patients could antibodies to SMS be detected. The effect of this somatostatin analogue is unlikely to be impaired by formation of endogenous antibodies, even after long-term treatment.
Fuessl
H S
HS
Department of Medicine, Royal Postgraduate Medical School, London, UK.
Domin
J
J
Anderson
J V
JV
Bloom
S R
SR
D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000276:immunology* / Q000627:therapeutic use; D011863:Radioimmunoassay
D015282:Octreotide